05.01.08
Indication: Joint pain
Source: Nutrition J, February 17, 2008;7:9
Research: Researchers recruited 70 adults (aged 25 to 75 years) with moderate to severe knee osteoarthritis (OA) to participate in a randomized, double-blind trial for 12 weeks. They consumed either glucosamine sulfate (1500 mg per day); Aquamin (2400 mg per day); combined treatment of glucosamine sulfate (1500 mg per day) and Aquamin (2400 mg per day); or placebo daily. Primary outcome measures were WOMAC scores and 6 minute walking distances (6 MWD). Laboratory-based blood tests were used as safety measures.
Results: Fifty subjects completed the study and analysis of the data showed significant differences between the groups for changes in WOMAC pain scores over time; however, these data must be reviewed with caution since significant differences were found between the groups at baseline for WOMAC pain and stiffness scores. Only the Aquamin and glucosamine groups demonstrated significant improvements in symptoms over the course of the study. The combination group (like the placebo group) did not show any significant improvements in OA symptoms in this trial. Within group analysis demonstrated significant improvements over time on treatment for the WOMAC pain, activity, composite and stiffness (Aquamin only) scores, as well as the 6 minute walking distances for subjects in the Aquamin and glucosamine treatment groups. The Aquamin and glucosamine groups walked 101 feet (+7%) and 56 feet (+3.5%) extra respectively. Researchers feel this small preliminary study suggests that Aquamin may reduce the pain and stiffness of knee OA over a 12-week period, but that it warrants further study.
Source: Nutrition J, February 17, 2008;7:9
Research: Researchers recruited 70 adults (aged 25 to 75 years) with moderate to severe knee osteoarthritis (OA) to participate in a randomized, double-blind trial for 12 weeks. They consumed either glucosamine sulfate (1500 mg per day); Aquamin (2400 mg per day); combined treatment of glucosamine sulfate (1500 mg per day) and Aquamin (2400 mg per day); or placebo daily. Primary outcome measures were WOMAC scores and 6 minute walking distances (6 MWD). Laboratory-based blood tests were used as safety measures.
Results: Fifty subjects completed the study and analysis of the data showed significant differences between the groups for changes in WOMAC pain scores over time; however, these data must be reviewed with caution since significant differences were found between the groups at baseline for WOMAC pain and stiffness scores. Only the Aquamin and glucosamine groups demonstrated significant improvements in symptoms over the course of the study. The combination group (like the placebo group) did not show any significant improvements in OA symptoms in this trial. Within group analysis demonstrated significant improvements over time on treatment for the WOMAC pain, activity, composite and stiffness (Aquamin only) scores, as well as the 6 minute walking distances for subjects in the Aquamin and glucosamine treatment groups. The Aquamin and glucosamine groups walked 101 feet (+7%) and 56 feet (+3.5%) extra respectively. Researchers feel this small preliminary study suggests that Aquamin may reduce the pain and stiffness of knee OA over a 12-week period, but that it warrants further study.